Apnimed Inc., a late-stage drug developer focused on sleep apnea, is seeking to raise as much as $160 million in a US initial public offering.
Finance Bloomberg Jul 27, 2026
Shionogi-Backed Apnimed Seeks to Raise $160 Million in US IPO
Apnimed Inc., a late-stage drug developer focused on sleep apnea, is seeking to raise as much as $160 million in a US initial public offering.
